Cystine

Phase 3Small molecule

UUniversity of Chicago

Cystine is one of 26 small molecule programs targeting HIV. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIVNot yet recruiting

HIVPhase 3

Not yet recruiting

Competition

Competitive Landscape

39 competitors in HIV

#DrugCompanyPhaseTrials

Tivicay

GSK

Approved

5 2

Cabenuva

GSK

Approved

3 3

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

6 4

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Fostemsavir

1 6

Selzentry

GSK

Phase 2

4 7

INCMGA00012

Incyte

Phase 3

1 8

Daraprim

CClinique Sainte Clotilde

Phase 2

2 9

Fosamax

OOrganon and Co

Phase 2

1 10

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Not yet recruiting

HIV

NCT06790342

Clinical

Trials by Indication[1]

HIV1 trial

Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya

Not yet recruiting·UUniversity of Chicago·Phase 3·NCT06790342·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cystine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cystine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cystine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Chicago

Cystine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

HIV1 trial

References

Drug Info

Quick Facts

Related News